Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Incyte

Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker

Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi.

Investors Business Daily

Top-Notch Medical Stocks Incyte, Haemonetics Beat — And Shares Crumbled

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics tumbled on its beat.

Investors Business Daily

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

9 Companies' Profit Set To Triple While S&P 500 In Free Fall

You might think fourth quarter earnings reports are ugly if you're just looking at the S&P 500. More than a few stocks buck the trend.

Investors Business Daily

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.

Investors Business Daily

Use This IBD Rating To Find Stock Market Leaders By Tracking Institutional Demand

Track institutional demand to find high-quality growth stocks approaching potential buy points.

Investors Business Daily

IBD Stock Of The Day Incyte Nears Buy Point After Winning A First-Ever Approval

IBD Stock Of The Day Incyte just won U.S. approval for a new skin treatment, leading Incyte stock to flirt with a breakout.

Investors Business Daily

3 Stocks the World's Greatest Investors Are Buying up Right Now

Skyrocketing inflation, the Fed’s aggressive interest rate hikes, and growing recession fears have kept the stock market under tremendous pressure lately. Amid the market’s downtrend, the world’s renowned investors are scooping up quality stocks Occidental Petroleum (OXY), Amazon.com (AMZN), and Incyte (INCY). Continue reading….

StockNews.com

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Image sourced from Shutterstock

Benzinga

Twitter And 3 Other Stocks Insiders Are Selling

US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

Global Cord Blood Stock Gains As FDA Announced Clearance To Study Blood Cancer Candidate

The U.S.

Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Benzinga

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Benzinga

4 Analysts Have This to Say About Incyte

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:

Benzinga

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Incyte Corporation's (NASDAQ:INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68. Sales increased 21% Y/Y to $733.24 million, missing the consensus of $750.66 million. The company's operating expenses increased 22% to $616.69 million, with the cost of sales up 45.8%, R&D costs up 15%,…

Benzinga

Incyte: Q1 Earnings Insights

Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

How To Attend Incyte Q1 2022 Earnings Conference Call

Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live webcast.

Benzinga

Why BriaCell Therapeutics Stock Is Surging Today

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.

1 2 3

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

325 stories

Amgen

314 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.